文献速递免疫规划传染病防控与疫情报告

TAK-003登革热疫苗的疫苗血症、减毒回复与安全性特征

Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program.
PubMed 文献 · Vaccine · 2026-07-24

本文汇总TAK-003登革热活疫苗临床开发项目数据,分析疫苗接种后疫苗RNA血症、减毒位点回复及其与病毒综合征样不良事件的关系。 pooled分析中54.8%受种者检出RNA血症,高峰在接种后第二周且多发生于首剂后;检出69个单一位点回复,相关不良事件多为非严重且未提示症状加重。RNA血症与短暂轻中度症状相关,但无RNA血症者亦可出现类似症状。

要点

  • TAK-003接种后约半数受种者出现短暂疫苗RNA血症,高峰在第二周且多发生于首剂后。
  • 检出69个单一位点减毒回复,相关不良事件多为非严重,未提示症状加重。
  • RNA血症者注射部位疼痛、头痛等 solicited AE 及 unsolicited AE 发生率略高。

核心结论

  • TAK-003接种后疫苗RNA血症常见但短暂,减毒回复未导致症状严重性增加,总体安全性特征可接受。

研究设计与样本

  • 汇总分析1/2期试验安全性数据,并对3期DEN-301和2期DEN-313试验中接种后30天内发热者检测RNA血症。

主要发现

  • pooled分析中441/805(54.8%)受种者检出TAK-003 RNA血症,血清阴性者占67.0%、血清阳性者占33.0%。
  • RNA血症高峰在接种后第二周,多数发生于首剂后,四个DENV组分均可检出但以DENV-2最常见。
  • DEN-301/DEN-313中1022例发热性疾病 investigated,39例检出RNA血症。
  • 检出69个单一位点回复,相关不良事件通常非严重且不提示症状加重。
  • 注射部位疼痛(无RNA血症42.0% vs 有RNA血症46.8%)和头痛(36.6% vs 37.6%)为最常见 solicited AE。

关键数值与推荐

  • 有RNA血症者疼痛、红斑、皮疹、关节痛和疲劳发生率高于无RNA血症者。
  • 有RNA血症者 unsolicited AE 发生率为62.4%,无RNA血症者为52.0%。
  • DEN-301/DEN-313中有发热性疾病者无论是否检出RNA血症,症状模式相似。

临床怎么用

  • 接种TAK-003后出现短暂轻中度症状可结合RNA血症检测解释,但无RNA血症者亦可出现类似症状,需综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Live-attenuated vaccines can replicate for a transient period post-vaccination and may be associated with symptoms resembling natural infection. The tetravalent dengue vaccine, TAK-003, has undergone extensive preclinical assessment to investigate vaccine RNAemia, viremia, genetic stability, and transmissibility. Here, we investigated the presence of vaccine RNAemia, attenuation loci reversions, and their association with viral-syndrome-like adverse events (AEs) in participants throughout the clinical development program. TAK-003 RNA positive serum samples were evaluated for viral replication and sequenced for reversions. Safety data (solicited AEs within 7/14 days; unsolicited AEs within 28 days) were assessed from a pooled phase 1/2 trial analysis. Participants who experienced febrile illness within 30 days post vaccination in the pivotal phase 3 DEN-301 trial and the phase 2 DEN-313 trial were tested for RNAemia and evaluated for AEs. TAK-003 RNAemia was detected in 441/805 (54.8%) of vaccinees (seronegative: 67.0%; seropositive: 33.0%) in the pooled analysis and in 39 participants with febrile illness from the DEN-301/DEN-313 trials (from 1022 febrile illnesses investigated). RNAemia peaked during the second week post-vaccination and mostly occurred after first dose. Although all four dengue virus (DENV) components were detected, RNAemia was most commonly due to DENV-2. 69 single locus reversions were detected; AEs reported in participants with reversions were generally non-serious, and not indicative of increased symptom severity. Pain at injection site (without RNAemia = 42.0%; RNAemia = 46.8%) and headache (without RNAemia = 36.6%; RNAemia = 37.6%) were the most frequently reported solicited AEs. Incidences of pain, erythema, rash, arthralgia, and fatigue were higher in participants with RNAemia. The incidence of unsolicited AEs was higher in participants with RNAemia (62.4%) than without (52.0%). In the DEN-301/DEN-313 analysis, participants with febrile illness showed a similar pattern of symptoms with and without RNAemia. The presence of RNAemia was associated with transient, mild-to-moderate symptoms, resembling natural infection, which were also observed in the absence of RNAemia.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tricou V, Saez-Llorens X, Kosalaraksa P, et al. Characterization of vaccine viremia, attenuation reversion, and safety: Combined results from the TAK-003 dengue vaccine clinical development program. Vaccine. 2026. PMID: 42497670. doi:10.1016/j.vaccine.2026.128917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。